Insulin lispro (ultra rapid formulation) - Eli lilly

Drug Profile

Insulin lispro (ultra rapid formulation) - Eli lilly

Alternative Names: LY-900014; URLi

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase I Diabetes mellitus

Most Recent Events

  • 06 Aug 2018 Eli Lilly plans a phase I trial for Healthy volunteers in Singapore (NCT03616977)
  • 12 Jul 2018 Eli Lilly completes a phase I trial for Type 1 diabetes mellitus in Japan (SC) (NCT03407118)
  • 23 Jun 2018 Pooled pharmacokinetics and efficacy data from three phase I studies in type-1 diabetes mellitus and type-2 diabetes mellitus released by Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top